Skip to main content
. 2013 Mar 5;29(5):1962–1968. doi: 10.3892/or.2013.2327

Table I.

Demographic and clinical characteristics of the patients and results of the tumors investigated.

Age/gender (years) Tumor site TNM HPV DNAa E6*I mRNAb Viral activityc SLPId Smoking habitse
1 47/M Lingual T T4N2bM0 − +++ >40 py
2 67/F Palatine T T2N0M0 HPV16 + Active + never
3 61/M Lingual T T3N2bM0 HPV16 Activef ++ na
4 61/M Palatine T T4N2bM0 − − >40 py
5 63/M Palatine T T1N2bM0 HPV16 + Active − na
6 53/F Palatine T T2N1M0 HPV16 + Active +++ >20 py
7 64/M Palatine T T1N1M0 HPV16 + Active − >20 py
8 70/F Palatine T T3N1M0 HPV16 + Active + never
9 60/M Lingual T T3N2bM0 HPV16 + Active − na
10 51/M Lingual T T2N1M0 HPV16 + Active + >20 py
11 76/M Lingual T T4N0M0 − ++ >20 py
12 53/M Palatine T T1N2aM0 ++ <20 py
13 52/M Palatine T T1N2bM0 HPV16 + Active + >20 py
14 54/M Palatine T T3N0M0 − ++ >40 py
15 59/M Palatine T T2N0M0 + + >40 py
16 47/M Palatine T T4N2bM0 − + >20 py
17 67/F Palatine T T3N2cM0 HPV16 + Active − never
18 72/M Lingual T T4N2bM0 − + na
19 63/M Palatine T T4N2cM0 HPV18 Activef − >40 py
20 68/M Palatine T T2N0M0 HPV16/18 + Active + >20 py
21 54/M Larynx T3N0M0 +++ >40 py
22 53/F Larynx T4N0M1 − − >20 py
23 72/M Larynx T3N0M0 HPV16 + Active − >20 py
24 52/F Larynx T2N2cM0 HPV16 + Active − na
25 69/M Larynx T2N0M0 − ++ na
26 70/M Larynx T4aN1M0 HPV16 Inactivef + >20 py
27 61/M Larynx T4N2bM0 − >40 py
28 55/M Larynx T3N2cM0 − + >20 py
29 73/F Larynx T3N2cM0 + + never
30 48/F Larynx T3N0M0 + ++ >20 py
31 58/M Larynx T3N2cM0 − ++ >40 py
32 73/M Larynx T3N0M0 − − >40 py
33 54/F Larynx T4N2cM0 HPV16 − Inactive − na
34 75/M Larynx T4aN0M0 +++ >20 py
35 54/M Larynx T3N1M0 + <20 py
36 55/F Larynx T3N0M0 ++ >40 py
37 58/M Larynx T4N1M0 + <20 py
38 56/M Larynx T3N0M0 − +++ >40 py
39 69/M Larynx T1N2cM1 − + >40 py
40 73/M Larynx T3N0M0 ++ >40 py
41 58/F Larynx T4N2cM0 + >20 py
42 64/M Larynx T3N3M0 + >20 py
43 56/M Tongue T4N3M0 ++ >40 py
44 57/M Tongue T4aN0M0 − ++ >40 py
45 53/M Tongue T4N2cMx +++ na
46 43/M Tongue T4N2cM0 − + >40 py
47 57/M Tongue T3N2bM0 HPV16 + Active − never
48 58/M Tongue T2N1M0 HPV16 + Active + >40 py
49 52/M Tongue T2N0M0 − ++ >40 py
50 44/M Tongue T2N0M0 ++ >20 py
51 64/M Soft palate T3N2cM1 − − >20 py
52 53/F Soft palate T1N2bM0 + >20 py
53 71/M Soft palate T3N2bM0 − + >40 py
54 52/M Soft palate T2N0M0 − + >40 py

M, male; F, female; T, tonsil; na, data not available; SLPI, secretory leukocyte protease inhibitor.

a

For final determination of HPV DNA status and genotyping, results of MPG Luminex-, LCD chip-HPV DNA detection and results of E6*I mRNA analysis were considered. Samples were defined as HPV DNA-positive when 2 of the 3 methods showed corresponding results.

b

Results of E6*I mRNA analysis; when no result is given, RNA was not available for analysis (n=17).

c

The HPV infection was considered biologically active when E6*I mRNA analysis and HPV DNA detection were positive for both parameters except for 3 casesf. For these cases, no RNA was available for analysis. However, HPV-positivity was confirmed in both DNA detection assays. In these cases, immunohistochemistry for p16INK4A was carried out (data not shown) with strong staining correlating with biological activity and weak staining correlating with biological inactivity.

d

SLPI antibody reactivity was scored on a semi-quantitative scale, according to Cordes et al(1). The correlation between SLPI and HPV status is statistically significant (P=0.005).

e

Tobacco smoking habits in packs per year (py).